IBB News and Press, iShares Biotechnology ETF From 12/11/23

2023-12-11 08:11:03 ET Summary US sectoral flows for November 2023 analyzed for impact on markets in December. Whopping $363 billion private sector surplus pointing to better markets in December. Fiscal flows expected to continue funding the economy and feeding the bull market...

2023-12-09 03:00:00 ET Summary The global markets experienced high volatility in 2023 due to factors such as high interest rates, bank failures, and a surge in bond yields. The macro environment in 2024 is expected to be complex and interesting, with rewards for investors who are ...

2023-12-04 08:13:57 ET More on market strategy Bears Refuse To Acknowledge New All-Time Highs In 2024 SPY Is A Buy According To The 200-Day Simple Moving Average When Do You Take Profits? S&P 500 hits new 2023 closing high to end week in which it notched ...

2023-11-23 01:39:17 ET Summary Shares of iShares Biotechnology ETF have been trading below their 40-month moving average for almost two years, indicating potential downside risk. The bearish divergences in the fund's RSI momentum indicator and MACD suggest a retest of the multi-ye...

2023-11-22 02:15:00 ET Summary Q3 earnings season had many familiar refrains relative to the year’s first two quarters. One difference was a return to positive earnings growth for the first time since Q3 2022. Not unlike the first two quarters of the year, earnings for ...

2023-11-21 21:11:32 ET Summary Tech-related stocks have performed poorly in 2023, with small-sized funds experiencing even worse losses. The iShares Biotechnology ETF and the SPDR S&P Biotech ETF have performed similarly so far in 2023. IBB is a large ETF with exposure to ...

2023-11-21 09:05:00 ET Summary A more volatile macroeconomic regime, alongside relatively high rates, may mean investors need to demand greater compensation for taking on equity risk; they can meet this higher performance bar by getting precise about targeted opportunities. The AI...

2023-11-20 00:24:09 ET Summary Biotech stocks have been heavily impacted by rising interest rates and the disruption caused by FTC-challenging acquisitions of biotechs. The equal-weight biotech ETF (XBI) has shown signs of a rebound after a prolonged downtrend, potentially due to ...

2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...

2023-11-15 08:16:54 ET More on Markets Oppenheimer favors tech amid upbeat prediction for S&P 500 Cathie Wood's ARK Invest launches crypto ETFs in partnership with 21Shares Nasdaq exits correction territory, small caps rebound in Russell revenge For furth...